Thus, targeting of IL-17 (the main pro-inflammatory cytokine associated with terminally differentiated Th17 cells) with the therapeutic monoclonal antibodies secukinumab or ixekizumab has proved highly successful in AS (37, 38) and psoriasis (39) but not IBD (40). The gene discussed is IL17A; the disease is inflammatory bowel disease.